OlympiA is a randomized, double-blind, parallel group, placebo-controlled multicenter Phase III study organized to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

This international study is sponsored by AstraZeneca and the NCI and is conducted through a collaboration of industry leaders, including the Jules Bordet BrEAST clinical trials unit, Breast International Group (BIG), Frontier Science, the NRG clinical trials group, and Myriad Genetic Laboratories.

Frontier Science provides project management, statistical leadership, design and analysis, randomization, data management, and programming. A separate firewalled Frontier Science statistical unit provides independent statistical analysis for OlympiA’s Data Monitoring Committee.